Novartis AG said a late-stage study showed its oral, once-daily BAF312, or siponimod, reduced the risk of disability progression in a severe form of multiple sclerosis.
The Phase III EXPAND study, the largest randomized, controlled study in secondary progressive multiple sclerosis (SPMS) to date, met its primary endpoint, compared with placebo, the Swiss drugmaker said in a statement on Thursday.
Source: Reuters
Filed Under: Drug Discovery
